Anna Vanazzi

767 citations

42 papers · 352 indexed · h-index 12

Impact in

Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment
Genetics top 10%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Pathology and Forensic Medicine 38
- Lymphoma Diagnosis and Treatment 37
Oncology 15
- Viral-associated cancers and disorders 7

Co-authors: Giovanni Martinelli (22 shared papers)Giovanni Paganelli (12 shared papers)Chiara Maria Grana (11 shared papers)Marta Cremonesi (8 shared papers)Pier Francesco Ferrucci (8 shared papers)Mahila Ferrari (6 shared papers)Giancarlo Pruneri (8 shared papers)Davide Radice (8 shared papers)
Journals: Blood (12 papers)Hematological Oncology (8 papers)Journal of Clinical Oncology (4 papers)British Journal of Haematology (2 papers)Blood Advances (2 papers)
Partner nations: Italy Switzerland United States

In The Last Decade

Anna Vanazzi

39 papers receiving 348 citations

Peers

Countries citing papers authored by Anna Vanazzi

Since Specialization

Citations

This map shows the geographic impact of Anna Vanazzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Vanazzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Vanazzi more than expected).

Fields of papers citing papers by Anna Vanazzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Vanazzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Vanazzi. The network helps show where Anna Vanazzi may publish in the future.

Co-authors

The 25 scholars most cited alongside Anna Vanazzi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anna Vanazzi Line = papers co-authored together Anna Vanazzi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03 Journal of Clinical Oncology ·Christian Taverna, Giovanni Martinelli, Felicitas Hitz, Walter Mingrone, Thomas Pabst, Lidija Čevreska, Auro del Giglio, Anna Vanazzi, Daniele Laszlò, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, Christine Biaggi Rudolf, Stéphanie Rondeau, Corinne Rusterholz, Ingmar Heijnen, Emanuele Zucca, Michele Ghielmini	2015	43
2	High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment Journal of Nuclear Medicine ·Marta Cremonesi, Mahila Ferrari, Chiara Maria Grana, Anna Vanazzi, Michael Stabin, Mirco Bartolomei, Stefano Papi, Gennaro Prisco, Giovanni Martinelli, Giovanni Paganelli, Pier Francesco Ferrucci	2007	36
3	High activity ⁹⁰Y‐ibritumomab tiuxetan (Zevalin^®) with peripheral blood progenitor cells support in patients with refractory/resistant B‐cell non‐Hodgkin lymphomas British Journal of Haematology ·Pier Francesco Ferrucci, Anna Vanazzi, Chiara Maria Grana, Marta Cremonesi, Mirco Bartolomei, Marco Chinol, Mahila Ferrari, Davide Radice, Stefano Papi, Giovanni Martinelli, Giovanni Paganelli	2007	33
4	Rituximab in Hodgkin lymphoma: Is the target always a hit? Cancer Treatment Reviews ·Kamal S. Saini, Hatem A. Azim, Emilia Cocorocchio, Anna Vanazzi, Monika Lamba Saini, Paola Rafaniello Raviele, Giancarlo Pruneri, Fedro A. Peccatori	2010	30
5	Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non‐Hodgkin's lymphoma British Journal of Haematology ·Giovanni Martinelli, Daniele Laszlò, Francesco Bertolini, Rocco Pastano, Patrizia Mancuso, Angelica Calleri, Anna Vanazzi, Paola Santoro, Franco Cavalli, Emanuele Zucca	2003	18
6	Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial Blood Advances ·Alden A. Moccia, Christian Taverna, Sämi Schär, Anna Vanazzi, Stéphanie Rondeau, Felicitas Hitz, Walter Mingrone, Thomas Pabst, Lidija Čevreska, Auro del Giglio, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, Céline Ruegsegger, Christine Biaggi Rudolf, Corinne Rusterholz, Stefanie Hayoz, Michele Ghielmini, Emanuele Zucca	2020	17
7	Efficacy of⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma Hematological Oncology ·Anna Vanazzi, Chiara Maria Grana, C. Crosta, Giancarlo Pruneri, Stefania Rizzo, Davide Radice, Antonio Pinto, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli	2013	17
8	High‐dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors Hematological Oncology ·Emilia Cocorocchio, Fedro A. Peccatori, Anna Vanazzi, Gaia Piperno, Liliana Calabrese, Edoardo Botteri, Laura Lavinia Travaini, Lorenzo Preda, Giovanni Martinelli	2012	16
9	Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer Clinical Cancer Research ·Pier Francesco Ferrucci, Cristina Rabascio, Chiara Mazzetta, Emilia Cocorocchio, Alberto Agazzi, Anna Vanazzi, Saverio Cinieri, Fedro A. Peccatori, Mara Paolucci, Francesco Bertolini, Giovanni Martinelli	2004	15
10	INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL Hematological Oncology ·Annarita Conconi, Annalisa Chiappella, Lorella Orsucci, Gianluca Gaïdano, Andrés J.M. Ferreri, Monica Balzarotti, Alessandra Tucci, Barbara Botto, Alden A. Moccia, Anna Vanazzi, Francesco Merli, Monica Tani, F. Espósito, L. Bonomini, Umberto Vitolo, Emanuele Zucca	2021	14
11	High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study. Blood ·Anna Vanazzi, Pierfrancesco Ferrucci, Mahila Ferrari, Liliana Calabrese, Marta Cremonesi, Mirco Bartolomei, Giovanni Paganelli, Giovanni Martinelli	2005	13
12	Chlorambucil–rituximab as first‐line therapy in patients affected by follicular non‐Hodgkin's lymphoma: a retrospective single‐centre study Hematological Oncology ·Giovanni Martinelli, Juan Montoro, Anna Vanazzi, Giovanna Andreola, Sarah Liptrott, Davide Radice, Mara Negri, Lorenzo Preda, Giancarlo Pruneri, Daniele Laszlò	2014	12
13	PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology ·Thomas E. Witzig, Kensei Tobinai, Luigi Rigacci, Tongyu Lin, Takashi Ikeda, Anna Vanazzi, Masayuki Hino, Yuankai Shi, Jiřı́ Mayer, Luciano J. Costa, Carlos Bermúdez, Jun Zhu, David Belada, Kamal Bouabdallah, Joseph Kattan, Cassandra Wu, Jenna Fan, Anne-Laure Louveau, Maurizio Voi, Franco Cavalli	2016	11
14	Who should be really considered as a poor mobilizer in the plerixafor era? Transfusion and Apheresis Science ·Giovanna Andreola, Anna Vanazzi, Davide Radice, Aleksandra Babić, Cristina Rabascio, Mara Negri, Giovanni Martinelli, Daniele Laszlò	2012	8
15	The Role of Dosimetry in the High Activity ⁹⁰ Y-Ibritumomab Tiuxetan Regimens: Two Cases of Abnormal Biodistribution Cancer Biotherapy and Radiopharmaceuticals ·Demetrio Aricò, Chiara Maria Grana, Anna Vanazzi, Mahila Ferrari, Andrew Mallia, Maddalena Sansovini, Giovanni Martinelli, Giovanni Paganelli, Marta Cremonesi	2009	7
16	Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03 Blood ·Christian Taverna, Giovanni Martinelli, Felicitas Hitz, Walter Mingrone, Thomas Pabst, Lidija Čevreska, Auro del Giglio, Anna Vanazzi, Daniele Laszlò, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, Emanuele Zucca, Christine Biaggi Rudolf, Stéphanie Rondeau, Corinne Rusterholz, Michele Ghielmini	2013	7
17	MRI features of breast implant-associated anaplastic large cell lymphoma British Journal of Radiology ·Anna Rotili, Federica Ferrari, Luca Nicosia, Filippo Pesapane, Valentina Tabanelli, Stefano Fiori, Anna Vanazzi, Lorenza Meneghetti, Francesca Abbate, Antuono Latronico, Enrico Cassano	2021	7
18	Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL Blood Advances ·Saveria Mazzara, Laura Lavinia Travaini, Francesca Botta, C. Granata, Giovanna Motta, Federica Melle, Stefano Fiori, Valentina Tabanelli, Anna Vanazzi, Safaa Ramadan, Tommaso Radice, Sara Raimondi, Giuliana Lo Presti, Mahila Ferrari, Barbara Alicja Jereczek‐Fossa, Corrado Tarella, Francesco Ceci, Stefano Pileri, Enrico Derenzini	2023	6
19	Confocal laser endomicroscopy diagnosis of gastric adenocarcinoma in a patient treated for gastric diffuse large-B-cell lymphoma Digestive and Liver Disease ·Cristina Trovato, Angelica Sonzogni, D. Ravizza, Giancarlo Pruneri, Marzia Rossi, G. De Roberto, D. Tamayo, Anna Vanazzi, Giancarla Fiori, C. Crosta	2008	6
20	High dose ⁹⁰Yttrium ibritumomab tiuxetan with PBSC support in refractory-resistant NHL patients: Preliminary results of a phase I/II study Journal of Clinical Oncology ·Anna Vanazzi, Pier Francesco Ferrucci, Chiara Maria Grana, Marta Cremonesi, Marco Chinol, Stefano Papi, Liliana Calabrese, Davide Radice, Giovanni Paganelli, Giovanni Martinelli	2006	4

About Anna Vanazzi

Anna Vanazzi is a scholar working on Pathology and Forensic Medicine, Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 42 papers that have together received 352 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (37 papers), Chronic Lymphocytic Leukemia Research (10 papers), Lung Cancer Treatments and Mutations (8 papers), CNS Lymphoma Diagnosis and Treatment (8 papers), Viral-associated cancers and disorders (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Breast Cancer Treatment Studies (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (252 citations), Genetics (80 citations), Oncology (162 citations), Radiology, Nuclear Medicine and Imaging (99 citations) and Neurology (52 citations). Anna Vanazzi has collaborated with scholars based in Italy, Switzerland and United States. Frequent co-authors include Giovanni Martinelli, Giovanni Paganelli, Chiara Maria Grana, Marta Cremonesi, Pier Francesco Ferrucci, Mahila Ferrari, Giancarlo Pruneri, Davide Radice, Mirco Bartolomei and Daniele Laszlò. Their work appears in journals such as Blood, Hematological Oncology, Journal of Clinical Oncology, British Journal of Haematology and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact